Bottom line
FTDZX vs IBB: the short answer
FTDZX (Franklin Biotechnology Discovery Fund) and IBB (iShares Biotechnology ETF) are both mutual funds.
But IBB is far broader, holding 254 positions to 126 for FTDZX, so beyond the top names it adds exposure FTDZX doesn't have.
IBB is cheaper at 0.44% vs 0.76% — a difference of $32 a year per $10,000 invested.
Over five years, FTDZX returned +6.4% a year vs +2.5% for IBB.
Updated Nov 19, 2026
FTDZX vs IBB side by side
| FTDZX | IBB | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Franklin Templeton | iShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.76% | 0.44% |
| Annual cost per $10k | $76 | $44 |
| 10-yr cost on $10k (prospectus) | $954 | $555 |
| Max front load | 0% | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +52.7% | +28.0% |
| 5-yr return (annualized) | +6.4% | +2.5% |
| 10-yr return (annualized) | +7.2% | +4.4% |
| Best quarter | — | +26.8% |
| Worst quarter | — | −22.9% |
| Net assets (fund) | $1.2B | $5.9B |
| Number of holdings | 126 | 254 |
| Portfolio turnover | 38% | 27% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
7 of FTDZX's top 25 holdings also appear in IBB's top 25.
| Holding | FTDZX | IBB |
|---|---|---|
| Amgen, Inc. | 4.39% | 7.50% |
| Gilead Sciences, Inc. | 3.86% | 7.52% |
| Regeneron Pharmaceuticals, Inc. | 3.77% | 5.70% |
| Argenx SE | 3.62% | 3.15% |
| Vertex Pharmaceuticals, Inc. | 3.54% | 7.66% |
| Insmed, Inc. | 1.99% | 2.95% |
| Neurocrine Biosciences, Inc. | 1.82% | 1.34% |
Source: SEC Form N-PORT
FTDZX top 10
- Jazz Pharmaceuticals plc — 5.66%
- Amgen, Inc. — 4.39%
- Gilead Sciences, Inc. — 3.86%
- Regeneron Pharmaceuticals, Inc. — 3.77%
- Argenx SE — 3.62%
- Vertex Pharmaceuticals, Inc. — 3.54%
- Franklin Institutional U.S. Government Money Market Fund — 3.18%
- Revolution Medicines, Inc. — 3.01%
- Guardant Health, Inc. — 2.76%
- Ascendis Pharma A/S — 2.56%
IBB top 10
- BlackRock Funds III — 13.18%
- Vertex Pharmaceuticals, Inc. — 7.66%
- Gilead Sciences, Inc. — 7.52%
- Amgen, Inc. — 7.50%
- Regeneron Pharmaceuticals, Inc. — 5.70%
- Alnylam Pharmaceuticals, Inc. — 5.68%
- IQVIA Holdings, Inc. — 3.18%
- Argenx SE — 3.15%
- Insmed, Inc. — 2.95%
- Mettler-Toledo International, Inc. — 2.49%
FAQ
What is the difference between FTDZX and IBB?
Which is cheaper, FTDZX or IBB?
Should I own both FTDZX and IBB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.